Dasatinib
Metastatic Prostate Carcinoma
St Vincent's Hospital, SydneySmall moleculePhase 2Active
B
57/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 48/ 100
- Competitive Position
- 73/ 100
Competitive context
251 Active assets in the Metastatic Prostate Carcinoma cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Fluciclovine VA Greater Los Angeles Healthcare System | Phase 4 | BBB |
LEUPROLIDE Mayo Clinic | Phase 4 | BBB |
Abiraterone Acetate Mayo Clinic | Phase 4 | BB |
PREDNISONE TABLETS Mayo Clinic | Phase 4 | BB |
Pembrolizumab CuraCell TX AB | Phase 2 | BB |
View all 50 →
Same molecule, other indications
Dasatinib is also rated in:
B-lymphoblastic leukemia/lymphoma with t(9;22)(q34.1;q11.2)Dormant
BB
Indicative ·
67 / 100
View asset →Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →